Date: 2014-10-08
Type of information: Development agreement
Compound:
Company: Saniona (Denmark) Ataxion (USA - MA)
Therapeutic area: Neuromuscular diseases
Type agreement: development
Action mechanism:
Disease: ataxia
Details: * On October 8, 2014, Saniona, a leading biotech company in the field of ion channels, announced that Saniona and Ataxion have extended their ongoing drug discovery and development collaboration with up to 12 months. Ataxion was established in 2013 by Atlas Venture Inc. (Boston) with the aim of developing one of Saniona’s research programs for treatment of ataxia. In July 2013, Saniona received ownership in Ataxion in exchange for Saniona’s rights to the active substances included in the so-called Ataxia-program. In addition to ownership in Ataxion, Saniona is also eligible to receive royalties on any potential products developed and commercialized from the Ataxia-program.
Saniona is responsible for key program discovery activities, which are conducted under a research and development agreement between Ataxion and Saniona. The initial term was 15 months.
Financial terms: According to the extended agreement, Saniona expects to receive research funding from Ataxion of approximately $0.8 million during the coming 12-month period. Ataxion has an option to extend the collaboration with Saniona against additional research funding.
Latest news:
